Brazilian customs and health authorities seized more than R$11 million worth of products labelled as retatrutide in the first three months of 2026, surpassing the total confiscated in all of 2025. The triple-hormone receptor agonist, developed by Eli Lilly for obesity and diabetes, has not been approved for sale in any country and remains in phase 3 clinical trials. Anvisa, the Brazilian health surveillance agency, confirmed this week that no registration application has been submitted anywhere, and the drug is still experimental. In parallel, the Emirates Drug Establishment disclosed it had taken enforcement measures against 71 sources—including 14 social‑media influencers—that were marketing or selling unapproved peptide‑based slimming products.

The molecule acts on GLP‑1, GIP and glucagon receptors. A phase 3 study with more than 2,300 adults, published in The Lancet, reported a mean body‑weight reduction of 28.3 percent in patients with type 2 diabetes using the highest dose. Despite the data, the manufacturer has not yet filed for regulatory review; the process requires completion of all pivotal trials and manufacturing‑quality assessments. In the meantime, a shadow market has emerged, fed by Paraguayan laboratories and promoted by Brazilian influencers via social‑media posts that, according to legal experts, may constitute indirect advertising of unregistered medicines prohibited under Brazilian law.

Regulatory responses are bifurcated. In Brazil, both the Federal Council of Medicine and the Federal Council of Dentistry have banned the use of polymethylmethacrylate (PMMA) for aesthetic purposes, confining it to strictly defined reparative indications; police sought to block the online accounts of a clinic owner accused of leaving at least 20 patients with severe complications from unapproved fillers. The UAE, meanwhile, referred 14 influencers to the National Media Office for breaching pharmaceutical advertising controls and launched field inspections of compounding pharmacies. In the United States, a Virginia federal judge ruled that the FDA failed to justify 2023 certification requirements for mifepristone prescribers, a decision that does not immediately strike down the rule but could lead to its invalidation when constitutional claims are heard later.

The next factual milestones are the FDA’s final decision on an advisory committee’s non‑binding recommendation to add six peptides to a compounding list—a move that would open a narrow, regulated pathway but not signal agency endorsement of safety—and further court proceedings on the mifepristone certification rule. For retatrutide, no regulatory filing date exists; the compound will only be submitted for approval once the clinical programme is complete and evaluated.